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Structured abstract 
 
Background: Studies of colorectal cancer (CRC) have suggested different mechanisms of 
carcinogenesis in men and women, young and old patients, right- and left sided tumors and sporadic 
and familial tumors. This might be reflected in morphology.  
Methods:  CRCs from 1613 patients operated 2004-2006 in Sweden were histologically reviewed.  
Morphology was correlated to sex, age groups, location and family history.  
Results:  Tumors in the right colon were larger, of higher stage, more often poorly differentiated, 
more mucin producing, more had often a peritumoral lymphocytic infiltrate and a high level of tumor 
infiltrating lymphocytes, and more seldom had an infiltrating margin than tumors in the left colon 
and rectum (p <0.0001 for most features). Young patients (<60 years) more seldom had multiple 
tumors but more often had perineural invasion, an infiltrative tumor margin, and high-stage tumors. 
Three features, TILs, medullary tumors and invasive tumor margin, were related to sex. Only vascular 
invasion was related to familiality.  
Conclusion: Location is the factor that has the most influence on tumor morphology. The results 
support the idea that different carcinogenic mechanisms may be involved in the right and left colon. 
Age is the most important determinant for the presence of multiple tumors and is a crucial factor for 
the aggressiveness of the disease.  
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Introduction 
The etiology of CRC is today considered to be influenced by environmental risk factors on a 
background of constitutional and acquired genetic variations. Strong genetic risk factors are known 
to confer a high risk of CRC in syndromes such as familial adenomatous polyposis (FAP) and Lynch 
syndrome. However, these syndromes explain less than 5% of all CRC. The remaining part is 
contributed by genetic risk factors of much smaller magnitude, as have been shown in studies of CRC 
as a complex disease [1]. Studies have suggested different mechanisms for tumor development in 
men and women, young and old patients and right- and left-sided tumors, as well as familial and 
sporadic tumors. 
 
Studies of CRC and sex have shown female patients to be older and to have more proximal and more 
poorly differentiated tumors than males [2, 3]. Two retrospective studies have reported more 
advanced stages of cancer in women compared to men [2, 4].  
Studies of the clinicopathological profile of CRC in relation to age have shown contradictory results. 
Fairley et al [5] reported that patients younger than 50 years had less localized and more distant 
disease, as well as a higher rate of poorly differentiated cancers. On the other hand, Heys et al [6] 
concluded in a review that patients younger than 45 years had a stage of disease similar to that in 
older patients but that they had had four times as many mucinous tumors, a feature associated with 
increased risk of local recurrence. In a retrospective population-based study from Iceland, individuals 
younger than 50 years more often had non-polypoid cancers, an infiltrating tumor border, vessel 
invasion, and lymph node metastases. Both younger men and older women showed a relatively high 
frequency of right-sided tumors [7]. 
When comparing CRCs in different locations, right-sided lesions show more aggressive features than 
left-sided as reflected in morphology and stage. Poor differentiation, mucinous type, larger size, 
higher TNM stage, vessel invasion, and expanding tumor border occur more frequently in right-sided 
lesions, while annular and polypoid growth and infiltrating tumor border are more common in left-
sided lesions [7]. Conversely, poorly differentiated adenocarcinomas and mucinous adenocarcinomas 
are more frequently seen in the right colon than in the left [8]. Right sided cancers also show a higher 
frequency of lymph-node-positive disease [9]. The frequency of right- and left-sided colon cancer 
differs by age, as noted above, with pronounced age-location differences in females [7]. Most CRCs 
are located in the sigmoid and rectum, but since the 1980s there has been a trend towards a change 
in distribution, with an increasing proportion of proximal tumors [10, 11].  
The majority of CRCs are sporadic and occur in individuals over 65 years of age [12]. Based on familial 
clustering it is estimated that 15-25% of CRCs have a potentially identifiable genetic cause, and 
among these are FAP and Lynch syndrome [12]. A high percentage of tumors in Lynch syndrome 
show microsatellite instability (MSI), which is also observed in 12-17% of sporadic CRCs [13]. A 
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unique histopathological phenotype with medullary or mucinous features, poor differentiation, a 
high number of tumor-infiltrating lymphocytes, and peritumoral Crohn-like lymphocytic infiltrate has 
been identified for MSI-tumors, as well as a better prognosis and a different response to 
chemotherapy [14, 15, 13]. Most cases of familial CRC do not fulfil the Amsterdam criteria for Lynch 
syndrome [16]. The morphology of the non-Lynch, non-FAP familial type of colorectal cancer has, 
according to our knowledge, not yet been studied. 
 
The aim of this study was to provide a detailed and systematic histopathological characterization of 
CRC in a large population-based cohort, the assumption being that the morphology could reflect 
different mechanisms of carcinogenesis. To that end, we compared the morphology of tumors in 
men and women, in different age groups, in different anatomical locations, and in sporadic and 
familial cases in order to isolate the effect of these four factors.  
 
Subjects, materials & methods 
Patients 
The recruitment of patients was done by the surgeon at surgery or after the surgery by using data 
provided by Regional Oncologic Centers. Letters were sent to the patients for invitation to the study. 
All patients who submitted an interest to participate were contacted over the telephone for 
informed consent and inclusion in the study.  A family history of cancer was taken from all study 
participants and all CRC diagnoses in the family were verified by medical records or death 
certificates.  
In total, 4585 patients were diagnosed with CRC in 14 hospitals in Middle-Sweden during the years 
2004-2006. General hospitals, district general hospitals and university clinics participated.  Of the 
2410 patients that were excluded, 639 died before they could be asked to participate or before blood 
testing could be performed and 1680 patients declined to participate or withdrew their consent 
during the study. Another 81 patients were not included for various reasons. In 1613 of the 
remaining 2175 patients, tumors were available for re-reviewing and constitutional DNA was 
available for genetic analysis (used in a previous study) [17]. Thus, 1613 was the number of tumors 
included in the analysis. When comparing the morphology of sporadic and familial cases of CRC, 
known cases of FAP (0.1%, n=2) or Lynch syndrome according to Amsterdam criteria (0,6%, n=9) or 
genetic testing (0.1%,n= 1) were excluded from the analysis.  Familial CRC was defined as patients 
with one or more first- or second-degree relatives with CRC. 
 
Pathology 
All tumors were re-reviewed according to a standardized protocol, which included information about 
the patients’ sex, age at operation, name of hospital and pathology department, date of diagnosis, 
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date of our re-evaluation, and name of re-reviewing pathologist. Tumor location and information 
about multiple synchronous tumors was gathered from the original pathology report as well as from 
the Regional Oncologic Center registry. Information on whether the patient had received pre-
operative chemo- and/or radiotherapy (for rectal cancers) was obtained from the clinical history on 
the pathology referral sheet and from lists provided by the Regional Oncologic Centers.  
All macromorphological parameters, including tumor size in three dimensions, were obtained from 
the original pathology report, as all CRCs in Sweden are examined in a standardized way according to 
a nationwide protocol. The number of positive and negative lymph nodes was noted, as well as the 
number of blocks taken (including large sections). 
In all cases Hematoxylin and eosin (H&E) stained slides were obtained from the pathology 
department. When slides could not be found in the archives new sections were prepared from 
paraffin blocks. In some cases additional immunohistochemical stainings (mainly CK7, CK20, CDX2 
and neuroendocrine markers) were available. In 0.4% of cases (n=6) only biopsy material was 
available since the patient never underwent surgery or the blocks from the surgical specimen were 
impossible to obtain. In an additional 2.0% of cases (n=33), the specimen consisted of a polypectomy 
or local resection. In many of these cases parameters such as peritumoral lymphocytic reaction, 
vascular or perineural invasion, co-existing polyps or tumor margin were impossible to assess, 
according to below. 
The micromorphological parameters assessed were tumor grade, stage, medullary features, mucin 
production, mucin type, Crohn-like peritumoral lymphocytic reaction, tumor infiltrating lymphocytes 
(TILs), desmoplasia, tumor necrosis, vascular invasion, perineural growth, co-existing polyps, budding 
and type of tumor margin. Attempts to diagnose any synchronous pathology of colon or rectum  
(e. g., inflammatory bowel disease, ulcers, fistulas, diverticulae etc) were made, but because 
adequate information was lacking in most cases no further analysis regarding this aspect was 
undertaken.  
Pure neuroendocrine tumors, recurrent carcinomas, metastases, gastrointestinal stromal tumors and 
other tumors of the colon or rectum were excluded. However, adenocarcinomas with some 
neuroendocrine differentiation were included in the study.  
In cases with complete regression of tumor due to preoperative chemo-/radiotherapy  (i. e., no 
tumor tissue for assessment) an attempt was made to obtain the preoperative biopsy sample for 
examination. 
In the analysis of necrosis, desmoplastic reaction, and budding, rectal cancers were excluded 
because, in most cases, they had received preoperative radiotherapy, which might have altered the 
morphology and affected the results. The Dworak regression grade for preoperatively treated tumors 
was not used. 
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Initially a small proportion of the cases (1.2%, n=20) was re-evaluated by two experienced 
gastrointestinal pathologists (S.G., N.P.) in order to establish consensus regarding the 
histopathological parameters. The remainder were examined by only one pathologist (S.G.). 
 
Tumor stage was recorded according to both the American Joint Committee on Cancer (AJCC) 
classification and the TNM system [18].  T1 tumors were not subclassified into Sm 1-3 and T3 tumors 
not into a-d because this was not common practice in Sweden when the study started.  For the same 
reason the R system for residual tumor (R0, R1, R2, RX), L for lymphatic invasion (L0, L1, LX) and V for 
venous invasion (V0, V1, VX) was not used. However, vascular invasion (lymphatic and/or blood 
vessel) was noted (Figure 1A).  
Tumor grade was determined according to the WHO classification [19]. Both the predominant and 
the second most common grade were noted in order to give a correct picture of the morphology. 
Tumors were classified into two grades of differentiation: poor (including poorly differentiated and 
undifferentiated) and other (moderately and well-differentiated). This was done due to the general 
difficulty in distinguishing moderately and well-differentiated tumors and because the distinction 
between poor and moderate differentiation is the most relevant clinically when it comes to 
prognosis and management [20]. 
Medullary carcinomas (sheets of undifferentiated epithelial cells with vesicular nuclei, prominent 
nucleoli, abundant pink cytoplasm, and prominent infiltration by intraepithelial lymphocytes) were 
coded separately.  Mucin production was divided into three categories: 0%, 0-50% and >50% of 
tumor area. Tumors containing more than 50% extracellular mucin were classified as mucinous and 
per definition low-grade according to Swedish consensus criteria and the WHO criteria[19]. Mucin 
type was noted as extracellular and/or signet-ring type (tumor cells with a large mucin vacuole filling 
the cytoplasm and displacing the nucleus).  
Lymphocytic reaction was recorded as Crohn-like if there were at least 4 nodular aggregates of 
lymphocytes deep to the advancing tumor margin in low power (x4) field [21]. TILs were categorized 
as ≤ 30/10 high-power field (HPF) and >30/10 HPF from H & E sections, always counting in the deeper 
half of tumor and avoiding adenomas, intramucosal carcinomas, and early invasive tumor 
components [22, 15, 23]. 
Desmoplasia was defined as a hypocellular intense fibrous reaction around infiltrating tumor tissue 
and was scored as present or absent. Tumor necrosis was defined as presence of cell detritus and 
inflammatory cells within glandular lumina, and was scored as present or absent.  
Vascular invasion was recorded when unequivocal tumor aggregates where found in preformed 
spaces lined by endothelium indicating lymphatic or blood vessels. Perineural growth was defined as 
tumor cells infiltrating underneath the perineurium at the invasive margin of the tumor or deep to it.  
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Co-existing polyps were recorded (based on the original report) as none, not assessable/not stated, 
tubular, tubulovillous, villous or serrated adenoma, or hyperplastic polyp. Data were, however, 
missing in too many cases to allow further analysis. The number of polyps, as well as the degree of 
dysplasia, high-grade or low-grade, was, however, noted.  
The presence or absence of budding, defined as detachment of single isolated cancer cells or a 
cluster of up to four cells, was recorded, as this has been shown to be an adverse prognostic factor 
[24]. Immunohistochemistry with cytokeratin and quantification of buds was, however, not 
performed.  
Tumor margin was classified as dominantly circumscribed (advancing with even, rounded infiltration) 
or infiltrative (invading foci identified) [25].  
 
Statistical analysis 
The analyses were done using Statview 5.0 (SAS Institute, Cary, NC, USA) and PASW Statistics version 
18 for Windows (SPSS, an IBM company, Chicago, IL, USA). Determination of the association between 
clinicopathological features and sex, age group, location, and family history was performed by 
univariate and multiple binary and multinomial logistic regression analysis for categorical outcomes 
and linear regression analysis for continuous outcomes.  Results are presented as odds ratio (OR) 
from the logistic regression and as regression coefficient (b) from the linear regression. The 
significance level for statistical tests was set at 0.05. 
In addition, factor analysis (extracting factors using principal components analysis) with variance 
maximizing (varimax) rotation was performed to form a concise description for all the variables 
included in the study. This analysis seeks a few underlying dimensions (factors) that account for 
patterns of variation among the variables in the study, in this case the clinicopathological parameters 
such as sex, age, location, and family history, as well as the morphological features.  Variables with 
loadings of > 0.40 usually are applied as meaningful loadings on the factor. If a variable has a 
meaningful loading on more than one component, that variable should be ignored in the 
interpretation. 
 
Results 
The total number of tumors was 1613; 100 patients had multiple synchronous cancers. Of the 
patients 52.6% were men (n=849) and 47.4% women (n=764). The mean age for men was 69.3 years, 
with median 70.0 and range 31-92 years. The mean age for women was 68.5 years, with median 69.0 
and range 27-95. Regarding age group, 18.8% (n=303) of the patients were younger than 60 years, 
50.3% (n=812) were aged 60-75 years, and 30.9% (n=498) were older than 75 years.  The percentage 
of tumors in each location were as follows: appendix 0.4% (n=7), caecum 14.4% (n=233), ascending 
colon 10.7% (n=172), hepatic flexure 4.0% (n=64), transverse colon 4.8% (n=78), splenic flexure 2.5% 
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(n=40), descending colon 3.7% (n=59), sigmoid colon 21.9% (n=354) and rectum 36,0% (n=581). 
Tumor location was unknown in 1.5% (n=25). Thus, 36.8% (n=594) of the tumors were located in the 
right colon (appendix through splenic flexure) and 25.6% (n=413) in the left colon (descending 
through sigmoid colon). Of the tumors 76.9% (n=1241) were sporadic and 20.6% (n=331) were 
familial.  In 1.7% (n= 29) the family history was unknown.   
 
Sex 
The univariate comparison between men and women (Table 1) showed that female patients 
significantly more often had tumors with TILs >30/10 HPF (OR 1.607, p<0.001) and tumors of 
medullary type (OR 1.861, p=0.009). Women also showed a lower frequency of tumors with 
infiltrative margin (OR 0.770, p=0.009). In the multivariate analyses (Table 5a) significant differences 
remained only in TILs >30/10 HPF (OR 1.482, p=0.002).  
 
Age 
The univariate comparison between the three age groups (Table 2) showed that patients aged < 60 
years had a significantly lower frequency of multiple tumors, mucin production  (0-50%), and TILs 
>30/10 HPF compared to the reference group (>75 years). They, however, showed a higher 
frequency of AJCC stage III tumors, N1 and N2/N3 tumors, vascular and perineural invasion, and 
infiltrative tumor margin. The highest levels of significance (p<0.001 or p=0.001) were seen for the 
differences in multiple tumors (OR 0.145), infiltrative tumor margin (OR 2.379), TILs >30/10 HPF (OR 
0.560) and perineural invasion (OR 1.892). In the multivariate analyses (Tables 5a and b), significant 
differences remained for multiple tumors (p=0.003), AJCC stage III (p<0.001), N2/N3 (p=0.004), 
perineural invasion (p=0.001), and infiltrative tumor margin (p<0.001). In addition, AJCC stage II and 
IV tumors and T4 tumors were significantly more common in the youngest age group. 
In the univariate analyses (Table 2) patients aged 60-75 years showed a lower frequency of mucin 
production (0-50%), TILs >30/10 HPF, and medullary-type tumors compared to the reference group, 
but a higher frequency of infiltrative tumor margin. The highest significances were seen for mucin 
production (0-50%) (OR 0.678, p=0.003) and infiltrative tumor margin (OR 1.417, OR=0.003). None of 
these differences, however, remained significant in the multivariate analyses (Tables 5a and b). 
 
Location 
In the univariate comparison (Table 3) most of the histological features studied showed a significant 
difference between the left colon and rectum compared to the right colon (reference group).  
The most significant differences (p<0.0001) between the left and right colon were seen in mean 
tumor diameter (1.138 cm smaller in left colon), T3 tumors (OR 0.356), proportion of poorly 
differentiated tumors (OR 0.223), mucin production (0-50%) (OR 0.327), mucinous type (>50%) (OR 
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0.336), TILs >30/10 HPF (OR 0.229), and medullary type (OR 0.112). All of the differences from the 
univariate analyses, except for the higher frequency of N2/N3 tumors in the left colon, remained 
significant in the multivariate analyses, where the highest level of significance (p<0.0001) was seen in 
tumor diameter, proportion of poorly differentiated tumors, Crohn-like reaction, TILs >30/10 HPF, 
medullary type, T3 tumors, and mucinous type (50%). 
In the univariate comparison between rectum and right colon, most of the features listed in Table 3 
showed highly significant (p<0.0001) differences. All of these significant differences remained in the 
multivariate comparison. 
 
Family history 
The only difference between the sporadic and the familial group seen in the univariate analyses 
(Table 4) was a higher frequency of vascular invasion in the familial cases (OR 1.412, p=0.016). This 
difference remained significant in the multivariate comparison (OR 1.438, p=0.012) (Table 5a). 
 
Factor analysis 
All the dependent and independent variables could be grouped into six different factors 
(components), as shown in Table 6.  
 
Discussion 
Sex 
In the univariate analyses tumors with TILs >30/10 HPF, medullary features, and circumscribed 
margin were more common in women than in men. The same was true for poorly differentiated 
tumors, although the OR did not reach significance (p=0.056). In the multivariate analyses only 
TILs>30/10 HPF remained significant. A high number of TILs, medullary features, circumscribed tumor 
margin, and poor differentiation are all features associated with MSI-positive tumors. The results 
support previous studies that have shown cancers with MSI-phenotype to be more common in 
women than in men [26, 15]. Differences in hormonal status between men and women could be a 
possible explanation. There is clinical evidence that estrogen protects against the development of 
CRC, but its exact role in carcinogenesis is not well understood. At least five isoforms of estrogen 
receptor beta (ERβ) are known and three of these are located in normal colon. Wong et al [27] 
showed that high ERβ1 expression was significantly associated with improved prognostic features 
such as lower grade, lower T stage, mucinous phenotype, and MSI-high (H) cancers. The authors 
suggested that ERβ1 expression is suppressed by estrogen and that decline in estrogen with 
menopause leads to an increase in ERβ1 expression and the subsequent development of MSI-H 
cancers. Older women have more MSI-cancers compared to younger women, in contrast to men, 
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where the frequency of MSI-cancers decreases with age. Thus, estrogen might preferentially protect 
against MSI-H cancers [28, 29].  
 
Age 
When comparing CRCs of different age groups we chose cut-off points at 60 and 75 years in order to 
get three groups of comparable size.  
Multiple synchronous tumors were clearly much less common (OR 0.145, p<0.0001) in the youngest 
group (<60 years) compared to the reference group (>75 years). The results suggest that age is a 
crucial factor for this feature. This may be due to young patients having a better anti-tumorigenic 
immune response, which prevents them from developing multiple cancers. Also, they may not yet 
have accumulated as many mutations as older patients in their colonic mucosa. Alternatively, the 
tumors of the young patients may be more fast-growing so that they will cause symptoms and be 
diagnosed before additional tumors have developed.  
Interestingly, patients aged less than 60 years showed more locally advanced tumors with more 
vascular and perineural invasion and infiltrative tumor margin. They also showed higher ORs for AJCC 
stage II-III, T4 and N2/N3 tumors than the reference group.  The results indicate that younger 
patients have a more aggressive disease. Looking at the univariate analysis, we noted that their 
tumors displayed less mucin production, less Crohn-like lymphoid reaction, more seldom showed 
medullary features, and, as well, had a lower frequency of TILs. These features constitute the 
opposite of the MSI-phenotype seen in older patients [14, 15, 13]. None of these features, however, 
remained significant in the multivariate analysis. All in all, the patient’s age seems to be correlated to 
tumor aggressiveness, rather than to morphology. The tumors of the young patients were more 
systemically advanced by the time of operation, thus indicating faster growth. 
 
Location 
Multiple tumors were much less common in rectum than in the right colon (OR 0.261, p<0.0001). 
This is probably for anatomical reasons: the short length of rectum and the narrow lumen result in 
symptoms and early discovery before any possible additional tumor could develop. The same 
anatomical factors probably explain why the tumors in left colon and rectum were smaller than the 
tumors in right colon. In addition to the larger lumen of the right colon, its bowel contents are also 
looser, which makes tumors in this local escape early detection by not causing symptoms such as 
obstipation. 
The tumors in the rectum, and to a certain extent in the left colon, tended to be of lower AJCC- and 
T-stage than those in the right colon. This characteristic might also be explained by the fact that 
these tumors are detected earlier. Interestingly, the tumors in the left colon tended to be of higher 
N-stage (OR 1.474 for N2/N3, p=0.024) than tumors in both the right colon and the rectum. There is 
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no obvious explanation for this finding, as there were no significant differences in the number of 
lymph nodes or number of lymph node metastases between the tumors in the three locations 
(statistics not shown). The difference in the frequency of vascular invasion was also non-significant.  
Mucinous tumors were common in the right colon compared to findings in both the left colon and 
the rectum. Because mucin production is a part of the morphological spectrum of MSI-tumors, which 
are more common on the right side, this is not surprising. The same was true for tumors with high 
number of TILs and medullary features, which are also characteristic of MSI-tumors (Figure 1B). 
The frequency of signet-ring cell morphology parallels that of mucin production as a whole, with 
tumors showing this feature being significantly more common in the right colon. Signet-ring cell 
carcinomas are rare, comprising 0.7-2.6% of all colorectal carcinomas [30]. These tumors have been 
shown to present themselves at a higher T-stage and with a higher number of positive lymph nodes 
than both conventional adenocarcinomas and mucinous adenocarcinomas without signet ring cells. 
They also show a poorer prognosis with a higher distant recurrence rate and decreased survival [30]. 
Genetic and immunohistochemical studies have shown that signet-ring cell carcinomas arise through 
a separate genetic pathway showing disruption of the E-cadherin/beta-catenin complex involved in 
cell-to-cell adhesion. They also display a goblet-cell phenotype with positivity for intestinal trefoil 
factor (ITF) and mucin-2, as well as a pattern of alterations in growth kinase-related oncogenes (K-
ras, BRAF), tumor suppressor genes (p53, p16), gene methylation, and Cox-2-expression different 
from that of conventional colorectal adenocarcinomas [30, 31].  
The rectal tumors showed more perineural invasion, and an infiltrative tumor margin was more 
frequent in both rectal and left sided cancers, compared with findings in right-sided cancers (Figure 
1C). Again, anatomical factors may lie behind this difference, as the rectum, which mainly consists of 
an outer longitudinal muscle without haustra and with its own mesentery, is innervated by a 
surrounding plexus of sympathic and parasympathic fibers. This, in turn, results in a high 
concentration of nerves close to the wall of the rectum. The limited space for luminal expansion in 
the rectum and left colon - because of the smaller diameter - may also force tumors in these 
locations to grow outward, hence causing a more infiltrative pattern. 
For most morphological parameters the differences seem to be greatest between right-sided colon 
cancers and rectal cancers. In addition, most features show a gradient from right colon to left colon 
to rectum, as indicated by the ORs. 
Most of the morphological features studied, such as multiple tumors, tumor diameter, grade of 
differentiation, mucin production, mucin type, TILs, medullary type, and tumor margin, seemed to be 
related to tumor location rather than to age group according to the multivariate analysis.  AJCC-, T- 
and N-stage also showed significant correlations to location.  
Different genetic abnormalities have been found in CRCs from different sites. Proximal CRCs are 
more often related to the MSI pathway, while distal cancers usually are associated with 
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chromosomal instability. Rectal cancer displays its own features with a significantly higher number of 
mutations than colon cancer, as well as the overexpression of nuclear beta-catenin, TP53, and Cox2 
[32]. These differences, which might be attributed to different embryological development and 
physiological mechanisms, may be reflected in different morphological features.  
 
Sporadic vs. familial 
There were remarkably few differences in the morphology between sporadic and familial CRCs. 
Familial CRC, however, showed a higher frequency of vascular invasion.  
In several studies vascular invasion was demonstrated to be prognostically significant by multivariate 
analysis, but no distinction was made between venous and lymphatic vessels [33]. Venous invasion 
has been found to be an independent prognostic factor in some univariate [34, 35] and multivariate 
analyses [36, 37, 38]. Similar results have been shown for lymphatic invasion [39, 40]. In some 
studies, location of the vascular involvement in extramural veins has been found to be of prognostic 
value [35]. The diagnosis of intravascular tumor growth is often difficult to make because fixational 
artefacts with retraction of tumor strands in fibrotic tissue can mimic vascular invasion. 
Reproducibility is low and interobserver variability is high. The frequency of vascular invasion is 
reported to vary from 10 to 89.5 % [41], with false negative rates between 10.5 and 29.6% if only 
H&E staining is used [42]. This frequency has also been shown to vary with number of blocks taken 
and if tangential sectioning is performed. In one study the frequency increased from 59% with two 
blocks examined to 96% with five blocks examined [43]. The assessment of vascular invasion may 
also be improved with immunohistochemical staining for endothelium or elastic tissue stains. 
Considering the complexity of the issue as discussed above, and  the retrospective nature of the 
study, as well as cost-, time- and labor-related aspects because of additional immunohistochemistry, 
we chose not to differentiate between venous and lymphatic invasion. Thus, our rate of vascular 
invasion, which is in the lower range of previously reported frequencies, might represent an 
underdiagnosis of this feature. 
The finding of a higher frequency of vascular invasion in familial tumors is, however, interesting and 
raises the question whether tumors in the familial group have different biological properties, such as 
specific tumor antigens or adhesion molecules that influence the ability to invade vessel walls. 
Protein markers such as apoptosis protease activating factor-1 (APAF-1), mammalian sterile20-like 
kinase (MST1), urokinase plasminogen activator receptor (uPAR) and Raf-1 kinase inhibitor protein 
(RKIP) have been associated with vascular invasion [44]. The urokinase plasminogen activator 
(uPA)/uPAR system is associated with degradation and regeneration of the basement membrane and 
extracellular matrix and uPAR itself is involved in cell movement and adhesion. RKIP has recently 
been characterized as a metastasis suppressor gene and loss of it has been associated with an 
increased frequency of distant metastases in CRC [44]. The expression of vascular endothelial growth 
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factor C (VEGF-C) in CRC has been linked to lymphatic vessel invasion, probably by VEGF-C promoting 
dilatation of lymphatic vessels and thereby facilitating the invasion of cancer cells [45]. All in all, 
these findings may speak for a difference between sporadic and familial CRCs in the expression of 
proteins facilitating vascular invasion, but immunohistochemical comparison of the two groups is 
required.  
One could expect that differences in vascular invasion between the two groups would be reflected in 
T and N stages. However, no such difference was evident. A higher frequency of vascular invasion 
should feasibly lead to more distant metastases, but M stage was not possible to assess in our 
material. A follow up of our patients after 5-10 years could perhaps reveal a correlation between 
vascular invasion and survival time, as has been shown in previous reports [38, 44].  
In our study we did not perform MSI analysis on our patients and it could therefore be argued that 
we have not omitted possible cases of Lynch syndrome from our hereditary group.  We, however, 
excluded 9 cases that fulfilled the Amsterdam criteria [16]. Mismatch-repair mutations have been 
found in up 90% of patients who meet these criteria [46]. We also excluded one case of Lynch 
syndrome that was diagnosed in a high-risk screening program. Judging from a previous study of a 
CRC population in Sweden [47] approximately 1.2% of the patients in our cohortshould have Lynch 
syndrome. Such a small proportion is not likely to have influenced the results much.  
 
Factor analysis 
We found that AJCC- and N-stage were in the same component (factor 1) together with vascular 
invasion, perineural invasion, budding, and tumor margin. This is not surprising because these are all 
features related to the extent of tumor spread and tumor aggressiveness. T-stage had a meaningful 
loading on two components and was therefore ignored in the interpretation. Mucin and mucin 
production were grouped into the same component (factor 2). Crohn-like peritumoral lymphocytic 
infiltrate is a part of the MSI spectrum, but in our analysis it was not grouped in the same component 
(factor 3) as the other MSI variables grade of differentiation (negative correlation to well/moderate), 
TILs, and medullary type. This finding supports the fact that peritumoral lymphoctic infiltration is a 
different entity from TILs and that it may have a different biological implication.  
Desmoplastic reaction and Crohn-like peritumoral lymphocytic infiltration were grouped together 
(factor 4). Desmoplastic reaction is generally thought of as a feature favoring the host by 
encapsulating the tumor, but there are conflicting reports [48]. The fifth component (factor 5) 
consisted of age group and multiple tumors. This is in keeping with the multivariate analysis which 
showed that patients younger than 60 years had significantly fewer multiple tumors than the 
reference group.   
In addition, our factor analysis showed a sixth component (factor 6), consisting of sex and age, which 
could be related to the fact that there was an age-related difference between men and women. 
14 
 
Location had a meaningful loading on both factors 4 and 5; however, this was not so high, at -0.41 
and -0.44, respectively. 
 
Because it seems reasonable that tumor morphology changes in relation to depth of invasion within 
the bowel wall, i.e., T-stage, we also performed such an analysis (Supplementary tables 1 and 2). A 
univariate analysis of T2, T3 and T4 tumors compared to T1 showed that high stage tumors were 
significantly larger and more often N1, poorly differentiated, and mucinous. They also showed Crohn-
like lymphocytic reaction, desmoplasia, necrosis, vascular invasion, budding, and infiltrative tumor 
margin more often than T1 tumors (p<0.0001 for most features).  In a multivariate comparison with 
our clinical parameters sex, age, localization and family history, T-stage was a significant factor for all 
morphological features possible to analyze except medullary type (p<0.0001 for T3 and T4 compared 
to T1 for the majority of features).  
 
Conclusion 
In this large and systematic study we have evaluated the clinicopathological characteristics of CRC in 
relation to sex, age, location, and family history. This is the largest study so far conducted on the 
morphology of familial non-Lynch, non-FAP patients.  Our results suggest that tumor location is the 
factor having most influence on morphology, with left-sided colon cancers and rectal cancers clearly 
differing from right-sided colon cancers. The results are in line with tumors in different locations 
having different genetic and embryologic backgrounds as well as developing in different physiological 
settings. Age is the most important determinant for the presence of multiple tumors and an 
important factor for the aggressiveness of the disease, as indicated by AJCC-, T- and N-stage.  The 
results could speak for a different mechanism of tumor development in young and old patients. Few 
morphological features are related to sex and almost none to family history.  
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Feature Men Women OR/b* p-value for 
OR/b 
> 1 tumors (%) 5.9 6.6 1.119 0.586 
Tumor diameter 
(mean. cm) 
4.8 4.7 -0.040 0.793 
AJCC stage  (%) 
       I 
       II 
       III 
       IV 
 
17.7 
39.6 
39.1 
3.6 
 
19.3 
39.6 
37.2 
4.0 
 
rc 
0.919 
0.874 
1.021 
 
 
0.550 
0.344 
0.942 
T (%) 
     1 
     2 
     3 
     4 
 
6.6 
17.1 
65.0 
11.4 
 
7.4 
16.2 
61.4 
14.9 
 
rc 
0.838 
0.836 
1.158 
 
 
0.435 
0.370 
0.534 
N (%) 
     0 
     1 
     2 or 3 
 
57.6 
24.0 
18.4 
 
60.0 
21.2 
18.9 
 
rc 
0.845 
0.986 
 
 
0.183 
0.915 
Proportion of poorly 
differentiated (%)** 
10.2 13.2 1.349 0.056 
Mucin production (%)     
0 % 59.5 59.5 rc  
0-50 % 25.6 25.6 0.998 0.989 
>50% (mucinous type) 14.9 14.9 0.998 
 
0.988 
Mucin type, if 
mucinous  (%) 
Only extracellular 
 
 
83.4 
 
 
85.4 
 
 
rc 
 
Signet-ring component 16.6 14.6 0.859 0.488 
Crohn-like lymphocytic 
reaction (%) 
64.2 68.1 1.193 
 
0.098 
TILs     
≤30/10 HPF 81.3 73.0 rc  
>30/10 HPF 18.7 27.0 1.607 <0.001 
Desmoplasia (%)  86.9 85.2 0.870 0.446 
Necrosis (%)  72.1 70.4 0.920 0.552 
Vascular invasion (%) 22.1 23.0 1.056 0.648 
Perineural invasion (%) 15.6 16.8 1.092 0.521 
Medullary type (%) 3.6 6.4 1.861 0.009 
Budding (%) 42.5 45.8 1.143 0.298 
Tumor margin (%)     
Circumscribed 48.4 55.0 rc  
Infiltrative 51.6 45.0 0.770 0.009 
*Females vs males. Odds ratio for all features except tumor diameter where difference b (cm) is stated.  
**In major tumor component. 
rc=reference category. 
 
 
 
 
Table 1. Univariate comparison of 
clinicopathological features of male and 
female patients with colorectal cancer. 
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Feature  
 
<60 yrs   60-75 
yrs 
     >75 yrs 
 Frequency* OR/b** p-
value** 
Frequency* OR/b*** p-
value*** 
Frequency* 
> 1 tumors (%) 1.3 0.145 <0.0001 6.7 0.773 0.229 8.5 
Tumor diameter (mean, cm) 4.8 -0.086 +0.624 4.7 -0.170 0.213 4.9 
AJCC stage  (%) 
       I 
       II 
       III 
       IV 
 
13.9 
35.0 
46.3 
4.8 
 
       rc 
1.231 
1.768 
1.948 
 
 
0.351 
0.009 
0.101 
 
19.4 
40.9 
36.1 
3.6 
 
rc 
1.037 
0.994 
1.068 
 
 
0.819 
0.969 
0.844 
 
19.6 
40.1 
36.8 
3.4 
T (%) 
     1 
     2 
     3 
     4 
 
6.1 
13.3 
66.2 
14.3 
 
rc 
0.837 
1.171 
1.345 
 
 
0.611 
0.606 
0.404 
 
7.4 
17.2 
62.2 
13.2 
 
rc 
0.904 
0.917 
1.035 
 
 
0.691 
0.702 
0.898 
 
6.9 
17.8 
63.4 
11.9 
N (%) 
     0 
     1 
     2 or 3 
 
49.5 
27.9 
22.6 
 
rc 
1.441 
1.788 
 
 
0.041 
0.003 
 
60.9 
20.1 
19.0 
 
rc 
0.845 
1.217 
 
 
0.243 
0.221 
 
60.7 
23.7 
15.5 
Proportion of poorly 
differentiated (%)† 
13.6 1.027 0.899 9.8 0.710 0.054 13.3 
Mucin production (%)        
0 % 62.5 rc  61.7 rc  54.1 
0-50 % 22.3 0.628 0.008 23.7 0.678 0.003 30.7 
>50% (mucinous type) 15.3 0.874 0.523 14.5 0.841 0.298 15.2 
Mucin type, if mucinous  (%) 
 
Only extracellular 
 
 
81.4 
 
 
rc 
  
 
87.1 
 
 
rc 
  
 
82.1 
Signet-ring component 18.6 1.044 0.884 12.9 0.678 0.113 17.9 
Crohn-like lymphocytic 
reaction (%) 
59.1 0.604 0.001 65.9 0.807 0.083 70.5 
TILs        
≤30/10 HPF 82.3 rc  78.6 rc  72.2 
>30/10 HPF 17.7 0.560 0.001 21.4 0.707 0.009 27.8 
Desmoplasia (%)  90.1 1.813 0.052 86.7 1.309 0.165 83.3 
Necrosis (%)  69.7 0.882 0.552 70.8 0.928 0.627 72.3 
Vascular invasion (%) 28.1 1.423 0.037 21.1 0.971 0.834 21.5 
Perineural invasion (%) 21.5 1.892 0.001 16.4 1.359 0.065 12.6 
Medullary type (%) 3.7 0.487 0.041 3.9 0.511 0.008 7.3 
Budding (%) 41.9 0.879 0.514 44.2 0.965 0.797 45.1 
Tumor margin (%)        
Circumscribed 38.5 rc  51.2 rc  59.8 
Infiltrative 61.5 2.379 <0.0001 48.8 1.417 0.003 40.2 
*Except for tumor diameter where size (cm) is stated. 
**OR and p-value for all features (except tumor diameter) present in age group <60 years vs. reference group (>75 
years). For tumor diameter difference b (cm) is stated. 
***OR and p-value for all features (except tumor diameter) present in age group 60-75 years vs. reference group (>75 
years). For tumor diameter difference b (cm) is stated. 
†In major tumor component. 
rc=reference category. 
 
Table 2. Univariate comparison of clinicopathological 
features of colorectal cancer in age groups <60, 60-75 
and >75 years. 
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Feature Right colon  Left colon   Rectum  
 Frequency* Frequency* OR/b** p-
value** 
Frequency* OR/b*** p-
value*** 
>  1tumors (%) 8.1 8.7 1.089 0.711 2.2 0.261 <0.0001 
Tumor diameter  
(mean, cm) 
5.6 4.5 -1.138 <0.0001 4.0 -1.586 <0.0001 
AJCC stage(%) 
       I 
       II 
       III 
       IV 
 
12.1 
47.0 
36.2 
4.8 
 
15.8 
38.1 
41.5 
4.6 
 
       rc 
0.619 
0.877 
0.741 
 
 
0.016 
0.511 
0.383 
 
27.2 
33.5 
37.4 
1.9 
 
rc 
0.316 
0.459 
0.181 
 
 
<0.0001 
<0.0001 
<0.0001 
T (%) 
     1 
     2 
     3 
     4 
 
3.4 
11.1 
69.1 
16.4 
 
8.6 
12.0 
62.3 
17.1 
 
rc 
0.424 
0.356 
0.412 
 
 
0.011 
<0.0001 
0.006 
 
9.4 
26.3 
58.8 
5.5 
 
rc 
0.852 
0.307 
0.121 
 
 
0.595 
<0.0001 
<0.0001 
N (%) 
     0 
     1 
     2 or 3 
 
61.0 
22.2 
16.7 
 
53.8 
24.5 
21.7 
 
rc 
1.250 
1.474 
 
 
0.163 
0.024 
 
60.4 
22.0 
17.7 
 
rc 
0.999 
1.086 
 
 
0.997 
0.687 
Proportion of poorly  
differentiated (%)† 
19.4 5.1 0.223 <0.0001 8.2 0.371 <0.0001 
Mucin production (%)        
0 % 
0-50 % 
>50% (mucinous type) 
42.7 
35.8 
21.5 
69.3 
19.0 
11.7 
rc 
0.327 
0.336 
 
<0.0001 
<0.0001 
 
69.5 
20.2 
10.3 
rc 
0.348 
0.295 
 
<0.0001 
<0.0001 
Mucin type, if  
mucinous (%) 
Only extracellular 
Signet-ring component 
 
 
78.6 
21.4 
 
 
88.8 
11.2 
 
 
rc 
0.464 
 
 
 
0.014 
 
 
91.3 
8.7 
 
 
rc 
0.349 
 
 
 
<0.0001 
Crohn-like lymphocytic 
reaction (%) 
83.6 73.6 0.548 <0.0001 42.1 0.142 <0.0001 
TILs        
≤30/10 HPF 61.9 87.7 rc  86.3 rc  
>30/10 HPF 38.1 12.3 0.229 <0.0001 13.7 0.257 <0.0001 
Desmoplasia (%) 86.6 85.2 0.889 0.522 ni ni ni 
Necrosis (%) 69.6 73.5 1.210 0.184 ni ni ni 
Vascular invasion (%) 23.2 20.5 0.853 0.311 23.3 1.005 0.973 
Perineural invasion (%) 12.9 17.1 1.359 0.065 19.0 1.587 0.005 
Medullary type (%) 11.8 1.5 0.112 <0.0001 0.2 0.013 <0.0001 
Budding (%) 46.2 41.3 0.820 0.128 ni ni ni 
Tumor margin (%)        
circumscribed 63.3 53.2 rc  37.9 rc  
Infiltrative 36.7 46.8 1.517 0.001 62.1 2.828 <0.0001 
Right colon=caecum through splenic flexure. Left colon=descendens and sigmoid. 
*Except for tumor diameter where size (cm) is stated.  
**OR and p-value for all features (except tumor diameter) present in left colon vs. reference group (right colon). 
For tumor diameter difference b (cm) is stated. 
*** OR and p-value for feature present (except tumor diameter) present in rectum vs. reference group (right 
colon). For tumor diameter difference b (cm) is stated. 
†In major tumor component. 
ni=Not included in comparison because of preoperative radiotherapy. 
rc=Reference category. 
Table 3. Univariate comparison of clinicopathological 
features of right sided colon cancers, left sided colon 
cancers and rectal cancers. 
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Feature Sporadic Familial OR/b* p-value for 
OR/b 
> 1 tumors (%) 6.6 4.2 0.626 0.113 
Tumor diameter 
(mean. cm) 
4.7 4.9 +0.132 0.368 
AJCC stage (%) 
       I 
       II 
       III 
       IV 
 
19.2 
39.3 
37.3 
4.1 
 
16.3 
39.1 
41.9 
2.8 
 
rc 
1.175 
1.325 
0.801 
 
 
0.380 
0.122 
0.572 
T (%) 
       1 
       2 
       3 
       4 
 
7.5 
16.9 
62.6 
12.9 
 
5.3 
16.5 
65.2 
13.0 
 
rc 
1.379 
1.478 
1.430 
 
 
0.293 
0.156 
0.258 
N (%) 
     0 
     1 
     2 or 3 
 
58.9 
22.5 
18.6 
 
57.5 
24.4 
18.1 
 
rc 
1.110 
1.001 
 
 
0.494 
0.994 
Proportion of poorly 
differentiated (%)** 
11.8 10.1 0.833 0.369 
Mucin production (%)     
0 % 60.1 58.8 rc  
0-50 % 24.7 29.0 1.200 0.202 
>50% (mucinous type) 15.2 12.2 0.821 0.305 
Mucin type, if 
mucinous  (%) 
Extracellular 
Signet-ring component 
 
 
84.5 
15.5 
 
 
84.2 
15.8 
 
 
rc 
1.020 
 
 
 
0.941 
Crohn-like lymphocytic 
reaction(%) 
65.6 68.4 1.135 0.346 
TILs     
≤30/10 HPF 77.5 76.8 rc  
>30/10 HPF 22.5 23.2 1.036 0.810 
Desmoplasia (%)  85.3 88.7 1.361 0.205 
Necrosis (%)  71.0 71.1 1.003 0.987 
Vascular invasion (%) 21.1 27.4 1.412 0.016 
Perineural invasion (%) 16.1 17.3 1.093 0.591 
Medullary type (%) 5.2 3.7 0.705 0.277 
Budding (%)  44.3 43.3 0.964 0.817 
Tumor margin (%)     
Circumscribed 52.4 48.0 rc  
Infiltrative 47.6 52.0 1.191 0.162 
*Familial vs. sporadic. Odds ratio for all features except tumor diameter where difference b (cm) is stated.  
**In major tumor component.  
rc= Reference category. 
 
 
 
 
 
 
 
 
Table 4. Univariate comparison of 
clinicopathological features in sporadic and 
familial colorectal cancer. 
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>1 tumors 
(Yes vs. No)
Tumor diam. 
(cm)
Differen-
tiation 
(Poorly vs. 
Other)*
Mucin type 
(Signet-ring 
component 
vs. Extra-
cellular)
Crohn-like 
reaction 
(Yes vs. No)
TILs 
(>30/HPF vs.  
≤ 30/10HPF)
Vascular 
invasion (Yes 
vs. No)
Perineural 
invasion (Yes 
vs. No)
Medullary 
type (Yes vs. 
No)
Tumor 
margin 
(Infiltrative 
vs. Circum-
scribed)
Sex
Male − − − − − rc − − − −
   1,482**
Female − − − − − p=0,002 − − − −
Age group
>75 yrs rc − − − − − − rc − rc
0,912 1,375 1,238
60-75 yrs p=0,683 − − − − − − p=0,059 − p=0,078
0,204 1,953 2,076
<60 yrs p=0,003 − − − − − − p=0,001 − p<0,0001
Localization
Right colon rc 5,612 rc rc rc rc − − rc rc
1,139 -1,138 0,231 0,484 0,554 0,230 0,115 1,461
Left colon p=0,586 p<0,0001 p<0,0001 p=0,021 p<0,0001 p<0,0001 − − p<0,0001 p<0,005
0,308 -1,576 0,361 0,346 0,140 0,242 *** 2,603
Rectum p<0,0001 p<0,0001 p<0,0001 p=0,001 p<0,0001 p<0,0001 − − p<0,0001
Family history
Sporadic − − − − − − rc − − −
1,438
Familial − − − − − − p=0,012 − − −
0,068 0,051 0,070 0,044 0,198 0,138 0,006 0,012 0,219 0,081Nagelkerke R Square†  
Desmoplasia, necrosis and budding omitted from table because these features were not included in any 
multivariate model.  
*In major tumor component. 
** Odds ratio for all features except tumor diameter where mean diameter and difference b (cm) is stated. 
***Odds ratio not possible to calculate because only one rectal cancer with medullary features present in the 
material. 
†Or Adjusted R Square. 
rc=Reference category. 
- =Not included in model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5a. Mutivariate analysis of clinicopathological 
features in relation to sex, age group, location and 
family history. 
26 
 
 
 
 
 
 
 
Age group
>75 yrs rc rc rc
1.263 0.921 0.863
II p=0.156 T2 p=0.751 N1 p=0.313
1.225 1.128 1.339
60-75 yrs III p=0.223 T3 p=0.607 N2/N3 p=0.078
1.360 1.591 −
IV p=0.366 T4 p=0.100
1.721* 0.943 1.399
II p=0.021 T2 p=0.872 N1 p=0.064
2.270 1.715 1.799
<60 yrs III p<0.0001 T3 p=0.096 N2/N3 p=0.004
2.904 2.353
IV p=0.012 T4 p=0.026
Localization
Right colon rc rc rc
0.617 0.422 0.328
II p=0.017 T2 p=0.012 0-50% p<0.0001
0.864 0.356 0.344
Left colon III p=0.473 T3 p<0.0001 >50% p<0.0001
0.708 0.407
IV p=0.320 T4 p=0.006 −
0.287 0.854 0.349
II p<0.0001 T2 p=0.607 0-50% p<0.0001
0.422 0.282 0.283
Rectum III p<0.0001 T3 p<0.0001 >50% p<0.0001
0.157 0.109
IV p<0.0001 T4 p<0.0001
Nagelkerke R Square** 0.055 0.087 0.011 0.080
AJCC-stage (II,III,IV vs. I) T-stage (T2,T3,T4 vs. T1)
N-stage (N1,N2/N3 vs. 
N0)
Mucinprod (0-50%, 
>50% vs. 0%)
 
Sex and family history omitted from the table because these factors were not included in the multivariate 
model for AJCC-, T- and N-stage or mucin production. 
AJCC-stage I, T1, N0 and 0% mucin are reference groups in analysis of AJCC-, T-, N-stage and mucin production. 
* Odds ratio.  
**Or Adjusted R Square. 
rc=Reference category. 
- =Not included in model. 
 
 
 
 
 
Table 5b. Multivariate analysis of clinicopathological 
features in relation to sex, age group, location and 
family history (continued). 
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Factor (component) 
1 2 3 4 5 6 
Sex .089 .000 .100 -.021 .149 .664 
Age group -.088 -.043 .042 .010 .601 -.318 
Localization 
Family history 
.031 
-.005 
-.213 
.022 
-.279 
-.043 
-.406 
.052 
-.438 
-.262 
-.184 
.529 
>1 tumor -.020 .084 -.046 -.133 .627 .070 
Tumor diameter -.075 .192 .356 .612 -.144 -.066 
AJCC-stage .711 .095 .021 .384 -.061 -.201 
T .441 .116 .011 .675 -.094 -.041 
N .707 .134 .061 -.053 -.039 -.263 
Differentiation -.183 -.126 -.815 -.018 .085 .046 
Mucin production -.033 .929 .030 .117 .043 -.017 
Mucin type .027 .894 .133 .141 .065 -.007 
Peritumoral* -.179 .025 .113 .496 .328 .250 
TILs -.289 .151 .571 .028 .167 .164 
Desmoplasia .180 -.071 -.315 .582 -.074 .041 
Necrosis .074 -.542 .013 .486 -.044 -.117 
Vascular invasion .531 -.078 .121 .006 -.080 .163 
Perineural invasion .626 -.026 -.081 -.029 -.034 .167 
Medullary type -.031 -.090 .854 .049 .029 .020 
Budding .506 -.269 -.006 .144 .244 .069 
Tumor margin .587 -.012 -.302 .054 -.086 .041 
       
Variables with loadings > 0,40 usually are applied as meaningful loadings on the factor. If a 
variable has a meaningful loading on more than one component, that variable should be 
ignored in the interpretation. 
A minus (-) before the value indicates a negative correlation. 
*=Peritumoral lymphocytic infiltration. 
Factor 1=Variables related to aggressiveness and extent of tumor spread. 
Factor 2=Variables related to mucin production/mucin type. 
Factor 3=Variables related to MSI-type of CRC. 
Factor 4=Tumor size, peritumoral lymphocytic infiltration and desmoplasia. 
Factor 5=Age group and multiple tumors. 
Factor 6=Sex and family history 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Factor analysis including both independent and 
dependent variables studied in relation to colorectal 
cancer morphology. 
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Figure legend 
Figure 1: A. Moderately differentiated colorectal cancer (CRC) showing venous invasion  
(x25, H & E staining). B. Right-sided CRC (caecum) displaying medullary features with poor 
differentiation, syncytial growth, tumor infiltrating lymphocytes (TILs) > 30/10 high-power field (HPF; 
not visible at this magnification), circumscribed tumor margin, and Crohn-like lymphoid reaction 
(x50, H & E staining). C. Left-sided CRC (sigmoid) with moderate differentiation, desmoplastic  
reaction, and infiltrative tumor margin (x25, H & E staining). 
 
 
 
 
 
